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The anti-cancer drug 5-fluorouracil is metabolized by
the isolated perfused rat liver and in rats into highly
toxic fluoroacetate
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Summary We report the first demonstration of the biotransformation of the anti-cancer drug 5-fluorouracil (FU) into two new metabolites,
a-fluoro-f-hydroxypropionic acid (FHPA) and fluoroacetate (FAC), in the isolated perfused rat liver (IPRL) and in the rat in vivo. IPRL was
perfused with solutions of pure FU at two doses, 15 or45 mg kg-' body weight, and rats were injected i.p. with 180 mg of FU kg-' bodyweight.
Fluorine-19 NMR analysis of perfusates from IPRL and rat urine showed the presence of the normal metabolites of FU and low amounts of
FHPA (0.4% or 0.1% of injected FU in perfusates from IPRL treated with 15 or 45 mg of FU kg-' body weight, respectively; 0.08% of the
injected FU in rat urine) and FAC (0.1% or 0.03% of injected FU in perfusates from IPRL treated with 15 or 45 mg of FU kg-' body weight,
respectively; 0.003% of the injected FU in rat urine). IPRL was also perfused with a solution of a-fluoro-i-alanine (FBAL) hydrochloride at
16.6 mg kg-' body weight dose equivalent to 15 mg of FU kg-' body weight. Low amounts of FHPA (0.2% of injected FBAL) and FAC (0.07%)
were detected in perfusates, thus demonstrating that FHPA and FAC arise from FBAL catabolism. As FAC is a well-known cardiotoxic poison,
and FHPA is also cardiotoxic at high doses, the cardiotoxicity of FU might stem from at least two sources. The first one, established in
previous papers (Lemaire et al, 1992, 1994), is the presence in commercial solutions of FU of degradation products of FU that are
metabolized into FHPA and FAC; these are formed over time in the basic medium necessary to dissolve the drug. The second, demonstrated
in the present study, is the metabolism of FU itself into the same compounds.
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5-Fluorouracil (FU) is widely used as an anti-tumour agent for
treatment ofsolid tumours. Its chiefside-effects are myelosuppres-
sion, diarrhoea, vomiting and mucositis. However, over the last
decade, the number of reports of cardiotoxicity and neurotoxicity
attributed to FU has rapidly increased, probably because ofthe use
of higher doses in continuous perfusion (Moertel et al, 1964;
Rezkalla et al, 1989; Moore et al, 1990; Gamelin et al, 1991; De
Fomi et al, 1992; Robben et al, 1993; Anand, 1994). The precise
biochemical mechanism underlying these two side-effects remains
unclear, although several investigators have postulated, but never
demonstrated experimentally, that FU might be transformed into
fluoroacetate (FAC), a highly cardiotoxic and neurotoxic poison
(Koenig and Patel, 1970; Okeda et al, 1990). FAC enters the Krebs
cycle and is then transformed into fluorocitrate, which inhibits the
enzyme aconitase. Aconitase catalyses the conversion ofcitrate to
isocitrate via the obligatory intermediate cis-aconitate. Inhibition
of aconitase leads to a build-up of citrate in animal tissues (in
particular heart) and serum, and the heart production of ATP is
severely limited. Toxicity and death are thought to be caused by
severe impairment of energy production (Pattison and Peters,
1966; Bosakowski and Levin, 1986; Keller et al, 1996).
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Having at our disposal a powerful method for studying the
metabolism of fluorinated drugs, in particular fluoropyrimidines
(Malet-Martino and Martino, 1992) we have been able to demon-
strate, using fluorine-19 nuclear magnetic resonance ('9F-NMR),
the biotransformation ofFU into two new metabolites, a-fluoro-,-
hydroxypropionic acid (FHPA) and FAC, in the isolated perfused
rat liver (IPRL) and in the rat in vivo. This transformation occurs
viaa-fluoro-p-alanine (FBAL), the main catabolite ofFU.
MATERIALS AND METHODS
Chemicals
FU, FAC and bovine albumin (fraction V) powder (ref. A9647)
were purchased from Sigma and chromium (III) acetylacetonate
(Cr(acac)3) from Aldrich (all from Sigma-Aldrich Chimie, 38297
Saint-Quentin Fallavier, France). FBAL hydrochloride was
provided by Tokyo Kasei Chemicals, Tokyo, Japan. 5,6-Dihydro-
6-hydroxy-5-fluorouracil (FUOH) was supplied by PCR,
Gainesville, FL, USA. All other chemicals were reagent grade and
obtained from standard commercial sources.
Synthesis of FHPA
FUOH (6.7 mg, 45 ,umol) was dissolved in 12 ml of 1 M potassium
hydroxide at ambient temperature and the mixture was stirred for
1 h (Lozeron et al, 1964). Sodium borohydride (2.3 mg, 60gmol)
was then added. After 15 min, the pH ofthe solution was adjusted
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Figure 1 '9F-NMR spectrum of a non-concentrated perfusate from an isolated perfused rat liver treated with FU (45 mg kg-' body weight) for 3 h, pH = 7.6,
number of scans 18 500
to -8.5 with 1 M perchloric acid. The precipitate was centrifuged
off and the supernatant freeze dried. The mass spectral and NMR
(IH, '9F, 13C) characteristics ofthe fluorinated compound obtained
were in accordance with the structure ofFHPA.
IPRL experiments
Male Wistar rats (Iffa Credo, Lyon, France) weighing 370-460 g
were used. The IPRL experiments have been described previously
(Arellano et al, 1997). The experiments were carried out with solu-
tions prepared immediately before use at two doses forFU (15 or45
mg kg-' body weight) and one dose for FBAL (16.6 mg kg' body
weight). The dose of 45 mg of FU kg' body weight was the
maximum dose that was almostentirely metabolized by the IPRL in
3 h in our perfusion conditions. The dose of 15 mg ofFU kg-' body
weight corresponds to 80 mg m-2 in humans (De Vita et al. 1993)
but, as the IPRLexperiment lasts 3 hinthepresence ofdrug inrecir-
culating mode, this dose corresponds to -600 mg m-2 day-' of FU
injected to humans as a continuous i.v. infusion, which lies within
the therapeutic range (500-1000 mg m-2 day-' for 4-5 days in
continuous i.v. perfusion). The dose of 16.6 mg of FBAL
hydrochloride kg-' body weight is equivalent to 15 mg of FU kg-'
body weight. After 1 h of liver equilibration, the drug was injected
into theperfusate andtheexperiments were continued for3 h. Atthe
end ofthe experiments, an aliquot ofthe perfusate was immediately
frozen to -80°C until '9F-NMR analysis. This medium was called
non-concentrated perfusate. The remaining perfusate was freeze
dried, stored at-80°C and resuspended in -3 ml of water immedi-
ately before '9F-NMR analysis. This represented the concentrated
perfusate. Lyophilization of non-concentrated perfusate induced an
increase in the pH of-0.7 pH unit (range0.5-0.9).
Effects of lyophilization on the behaviour of FBAL
In basic medium, bicarbonate ions react with FBAL to give N-
carboxy-a-fluoro-P-alanine (CFBAL), the proportion of which
with respect to FBAL increases with pH up to about pH 9 (Martino
et al, 1987). The perfusion medium containing HCO3-, FBAL and
CFBAL were observed in the non-concentrated perfusate (Figure
1). The proportion of CFBAL relative to FBAL is much higher in
the concentrated perfusate (compare Figures 1 and 2) as the pH
increased after lyophilization.
The lyophilization ofthe perfusate led to the appearance of two
signals at a chemical shift (8) = -111.1 and -110.4 p.p.m. in the
19F-NMR spectra ofconcentrated perfusates from FU experiments
(Fig. 2) and four signals at -111.1, -111.2, -110.3 and
-110.4 p.p.m. in the '9F-NMR spectra of concentrated perfusates
from FBAL experiments (Figure 3). Two experiments were carried
out to show that these signals corresponded to adducts of FBAL
with f- and a-glucose. First, 2.5 mg ofcommercial racemic FBAL
hydrochloride was added to a perfusate containing neither bicar-
bonate (to avoid significant formation of CFBAL) nor glucose.
After freeze-drying and dissolution of the residue in water, the
'9F-NMR spectrum of this sample exhibited a sole signal at
-112.7 p.p.m. corresponding to FBAL. After addition of 30 mg of
glucose, four signals appeared. Two strong signals of equal inten-
sity at -111.1 and -111.2 p.p.m. corresponded to the two dia-
stereomeric adducts of racemic FBAL with [-glucose (FBAL
[R]-gluc,B and FBAL [S]-gluc[B). The two other weak signals of
equal intensity at -110.3 and -110.4 p.p.m. corresponded to the
two diastereomeric adducts of racemic FBAL with a-glucose
(FBAL [S]-gluca and FBAL [RI-gluca). Furthermore, addition of
this sample to a concentrated perfusate from IPRL treated with FU
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Figure 2 "9F-NMR spectrum of aconcentrated perfusate from an isolated perfused rat liver treated with FU (15 mg kg-'body weight) for 3h, pH =8.3,
number of scans 20750
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Figure 3 "9F-NMR spectrum of aconcentrated perfusate from an isolated perfused rat liver treated with FBAL hydrochloride (16.6 mg kg-' body weight) for 3h,
pH = 8.3, number of scans 20200
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Table 1 '9F-NMR characteristics of (1) authentic standards of a-fluoro-,B-hydroxypropionic acid (FHPA) and fluoroacetate (FAC) in a concentrated
blank perfusate (pH = 8.4) and (2) FHPA and FAC before and after their addition to a concentrated perfusate (pH = 8.3) from an isolated perfused rat
liver experiment at 15 mg of FU kg-' body weight
FHPA FAC
6 (p.p.m.)a MUltipliCityb JHF (Hz)c 6(P.p.m.) Multiplicityb JHF(Hz)c
Authentic standards -113.7 ddd 2J 50.0 -141.4 t 2J 48.0
3J 30.9, 24.1
Before addition -113.7 ddd 2J 50.3 -141.4 t 2J 49.0
3J 29.5, 24.9
After addition -113.7 ddd 2J 50.4 -141.4 t 2J 48.0
3J 30.2, 24.4
a'F-NMR 6 are related to external trifluoroethanoic acid (5% (w/v) aqueous solution). bd, Doublet; t, triplet. cThe slight differences in the J values are
due to the low digital resolution of the spectra (1.3 Hz per point).
Table 2 Comparison of the amounts of unmetabolized drug and metabolites in perfusates of isolated perfused rat livers treated with FU at 45 (n = 4) or
15 (n = 5) mg kg-' body weight or FBAL at 16.6 mg kg-' body weight (n = 4) for 3 h
Experiments with FU at Experiments with FU Experiments with FBAL
45 mg kg-' body weight at 15 mg kg-' body weight at 16.6 mg kg-' body weight
lmol g-' of liver Percentage with lmol g-' of liver Percentage with ,umol g-' of liver Percentage with
respect to Injected FU respect to injected FU respect to injected FBAL
FU 0.36±0.40 3.1 ±3.7 0 0 0 0
F- 0.48±0.15 4.0±0.9 0.91 ±0.32 21.4±6.8 0.58±0.16 16.1 ±5.6
-110.1 p.p.m. 0.05±0.02 0.4 ±0.1 Oa Oa 0 0
FUPA 0.17 ± 0.04 1.4 ± 0.2 0.02 ± 0.03 0.6 ± 0.7 0 0
FBAL + CFBAL 6.73 ± 0.87 56.3 ± 6.7 1.28 ± 0.38 30.3 ± 8.6 1.60 ± 0.57 43.1 ± 11.0
Total catabolites 7.43 ± 0.94 62.1 ± 6.0 2.22 ± 0.32 52.3 ± 5.3 0.58 ± 0.16 16.1 ± 5.6
FHPAb 0.014 ± 0.003 0.12 ± 0.02 0.018 ± 0.004 0.42 ± 0.06 0.006 ± 0.0008 0.18 ± 0.04
FACb 0.004 ± 0.0002 0.03 ± 0.005 0.005 ± 0.002 0.11 ± 0.04 0.0025 ± 0.0002 0.07 ± 0.007
aOnly observed in one experiment out of five, representing 0.02lmol g-' of liver and 0.5% of injected FU. bFHPA and FAC could only be assayed in the
concentrated perfusate.
and thus only containing metabolic FBAL in the [R] configuration
led to an increase in the signals at -110.4 p.p.m. (FBAL [R]-
glucax) and-111.1 p.p.m. (FBAL [R]-gluc,3).
Rat urine
Eight rats were injected i.p. with a solution ofpure FU at a dose of
180 mg kg-' body weight. This dose corresponds to -950 mg m-2
in humans (De Vita et al, 1993), which lies in the upper part of
therapeutic range. Urine samples were collected over 24 h after the
injection in two 12-h fractions. They were immediately frozen and
stored at -80°C until 19F-NMR analysis.
NMR spectroscopy
'9F-NMR spectra were recorded at 282.4 MHz on a BrukerWB-AM
300 spectrometer intheconditions describedpreviously (Arellano et
al. 1997). The pulse interval was 1.4 s for quantification ofconcen-
trated perfusates and 3.4 s for quantification of non-concentrated
perfusates and urine samples. Cr(acac)3 was added to non-concen-
tratedperfusates andurine samples. With theNMRrecordingcondi-
tions used, fully relaxed spectra were obtained as the intensities of
the signals were not affected by recording the spectra with a much
longer repetition time (10 s). Peak areas were therefore directly
proportional to concentrations. The 8 values were reported relative
to the resonance peak of trifluoroethanoic acid (5% (w/v) aqueous
solution) used as external chemical shift reference.
We determined the amounts of FU and its different already
known catabolites from the values measured in the non-concen-
trated perfusates. '9F-NMR is not a very sensitive analytical tech-
nique. The detection threshold depends on the spectrometer
magnetic field: -5 ,UM with our 7-Tesla spectrometer (Malet-
Martino and Martino, 1992), -3 ,UM with a 9.4-Tesla spectrometer
(Kamm etal, 1996), -1-2 ,UM with a 11.7-Tesla spectrometer (Hull
et al, 1988). As FHPA and FAC concentrations did not reach this
limit in the non-concentrated perfusates (maximal concentrations
<2 g1M for FHPA and <1 ,UM for FAC as estimated from assay of
concentrated perfusates), these compounds were not detectable.
We therefore determined their concentrations from the spectra of
the concentrated perfusates in which FHPA and FAC concentra-
tions were .10gIM and thus could be accurately assayed.
RESULTS
IPRL experiments with FU or FBAL
Qualitative analysis
IPRL were treated with pure FU at two doses, 45 mg kg-' body
weight (n = 4) or a 'therapeutic' dose of 15 mg kg-' body weight
(n = 5) for 3 h.
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Table 3 Urinary excretion of FU and metabolites in rats treated with pure
FU at 180 mg kg-' body weight
Compound Fraction 0-12 h Fraction 12-24 h
Unmetabolized FU 18 ± 11 0.1 ± 0.1
FUH2 0.04 ± 0.03 0.004 ± 0.003
FUPA 1.1 ±0.5 0.2 ±0.2
FBAL 28±7 4±4
F- 4 1 1 1
FHPA 0.08 ± 0.02 0.03 ± 0.02
FAC 0.003 ± 0.002 0.001 ± 0.001
Total catabolites 33 7 5 5
Total excreted 51 17 5 5
Table 4 Comparison of the performances of the current analytical
techniques for FAC determination
Method Minimal amount of Minimal amount of FAC
FAC detecteda required for the entire
(nmol) assaya (nmol)
HPLC 0.01 200b
(Ray et al, 1981)
HPLC 0.015 20c
(Kramer, 1984)
GC 5x10-5-10-4 2d
(Okuno et al, 1982)
GC 0.3c
(Ozawa and Tsukioka, 1987)
Capillary GC 10 or ice
(Burke et al, 1989)
Headspace GC 5c
(Mori et al, 1996)
Bioassay 25'
(Wong et al, 1995)
19F-NMR 10 10
(this study)
aFAC was previously derivatized for all GC and HPLC assays. bFrom canine
gastric content fortified with FAC. cFrom water fortified with FAC. dFrom
coyote stomach fortified with FAC. eLimit of detection with flame ionization
detector or selected ion monitoring-GC/MS respectively. 'From bait materials
fortified with FAC.
A characteristic '9F-NMR spectrum of a non-concentrated
perfusate shows the signals of FU at 6 = -93.3 p.p.m. (except in
the experiments at 15 mg kg-' body weight, in which the drug was
entirely metabolized) and its main catabolites, a-fluoro-f-ureido-
propionic acid (FUPA) at -110.7 p.p.m., FBAL at -112.4 p.p.m.,
CFBAL derived from the interaction of bicarbonate ion with
FBAL (Martino et al, 1987) at -110.9 p.p.m. and fluoride ion (F-)
from the defluorination ofFBAL (Martino et al, 1985; Porter et al,
1995) at -43.5 p.p.m. A weak additional signal at -110.1 p.p.m.
corresponding to an unknown compound was observed in the
spectra of perfusates from experiments at 45 mg of FU kg-' body
weight and in one out of the five experiments at 15 mg of FU kg-1
body weight. 5,6-Dihydro-5-fluorouracil (FUH2) was not observed
in any ofthe experiments (Figure 1).
A characteristic '9F-NMR spectrum of a concentrated perfusate
from an IPRL treated with FU (Figure 2) shows the signals of FU
at -93.2 p.p.m. (except in the experiments at 15 mg kg-1 body
weight), FBAL at-112.7 p.p.m., CFBAL at-111.5 p.p.m. and F- at
-49.7 p.p.m. The differences in the values of6 in non-concentrated
and concentrated perfusates are mainly due to the much higher
ionic strength in the concentrated perfusates and to differences in
pH (7.6 vs 8.3 respectively). The strong resonance at -111.1 p.p.m.
and the weak signal at -110.4 p.p.m. are artifacts offreeze-drying.
These two signals correspond to adducts of metabolic FBAL in
the R configuration (Gani et al, 1985) with f-glucose (FBAL
[R]-glucp, 6 = -111.1 p.p.m.) and a-glucose (FBAL [R]-gluca,
6 = -110.4 p.p.m.) as demonstrated in the Materials and methods
section. The two signals at -113.7 p.p.m. and -141.4 p.p.m. were
assigned to FHPA andFAC, respectively, and were positively iden-
tified by spiking a perfusate with authentic standards. The
recording of'H-coupled or-decoupled '9F-NMR spectra after addi-
tion of authentic FHPA and FAC to a concentrated perfusate from
an IPRL experiment at 15 mg of FU kg-' body weight showed an
increase in the signals located at-113.7 and-141.4 p.p.m., respec-
tively, with the same coupling constants (Table 1).
IPRL (n = 4) were treated with commercial racemic FBAL at a
dose of 16.6 mg kg-' body weight, dose equivalent to 15 mg of
FU kg-' body weight. A characteristic 19F-NMR spectrum of a
non-concentrated perfusate shows the signals of FBAL at
-112.4 p.p.m., CFBAL at -110.9 p.p.m. and F- at -43.5 p.p.m. A
characteristic 19F-NMR spectrum of a concentrated perfusate
(Figure 3) shows the signals ofFBAL at -112.7 p.p.m., CFBAL at
-111.5 p.p.m., F- at -49.7 p.p.m., the four adducts of racemic
FBAL with glucose (FBAL [R]-glucp, 6 = -111.1 p.p.m.; FBAL
[S]-gluco, 6 = -111.2 p.p.m.; FBAL [R]-glucax, 6 = -110.4 p.p.m.;
FBAL [S]-glucax, 6 = -110.3 p.p.m.), FHPA at -113.7 p.p.m. and
FAC at-141.4 p.p.m.
The control experiments previously described (Arellano et al,
1997) have unambiguously shown that FAC and FHPA did not
arise from a chemical transformation of FU or FBAL taking place
during the perfusion experiment or the freeze-drying step but were
formed via a metabolic process.
Quantitative analysis
We determined the amounts ofunmetabolized FU (in the 45 mg of
FU kg-' body weight experiments), its differentcatabolites (FUPA,
CFBAL, FBAL, F-) and the unknown compound at -110.1 p.p.m.
from the values measured in the non-concentrated perfusates. For
FBAL experiments, the amounts of unmetabolized FBAL and F-
were determined in the non-concentrated perfusates. As FHPA and
FAC were not detectable in the non-concentrated perfusates, we
determined their concentrations from the spectra of the concen-
trated perfusates. It should be noted that the amounts of FHPA
and FAC were underestimated as demonstrated previously
(Arellano et al, 1997).
Table 2 shows the results of the IPRL experiments. All FU was
metabolized at the 15 mg kg-' body weight dose, whereas at
45 mg kg-' body weight only 3± 4% ofthe injected FU was recov-
ered unchanged in the perfusate. The amount of total catabolites
(FUPA + CFBAL + FBAL + F- + the compound resonating at
-110.1 p.p.m. when present) increased as a direct function of the
injected FU dose. At45 mg ofFU kg-' body weight, FBAL was by
far the main catabolite as it represented 91% of the metabolites of
FU whereas F- made up only 6%. At 15 mg of FU kg-' body
weight, FBAL and F- represented 58% and 41%, respectively, of
FU metabolites. Only small amounts of FHPA and FAC were
found in the perfusates: FHPA represented 0.4% or 0.1% and FAC
0.1% or 0.03% of the injected FU (15 or 45 mg of FU kg-' body
weight respectively). There was no significant difference in the
amounts for the two doses of FU (Student's t-test, 0.05 < P < 0.1
for FHPA and 0.1 <P < 0.375 for FAC).
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In FBAL experiments, F- was the main metabolite and repre-
sented 16% of the injected FBAL dose. Low amounts of FHPA
and FAC were also found in the perfusates. The difference
between their amounts and those determined in FU 15 mg kg-'
body weight experiments was significant (Student's t-test,
P < 0.0005 for FHPA and 0.025 < P < 0.05 for FAC).
Rat experiments
To check that FU was also metabolized into FHPA and FAC in
vivo, a solution ofpure FU was injected i.p. toeight rats at a dose
of 180 mg ofFU kg-' body weight. Urine samples were collected
over 24 h after the injection in two 12-h fractions and analysedby
'9F-NMR. A characteristic '9F-NMR spectrum shows thesignals of
FU (6 = -93.3 p.p.m.) and its catabolites, FUH2 at -126.0 p.p.m.,
FUPA at -110.6 p.p.m., CFBAL at -110.8 p.p.m. (when sample
pH >7.5), FBAL at -112.3 p.p.m. and F- at -42.6 p.p.m. FAC was
detected at -140.9 p.p.m. in six and in three out of the eight
samples analysed for each fraction 0-12 h and 12-24 h respec-
tively. At the natural pH of urine samples (pH 6.2-8.2), FHPA,
which was observed in all samples, produced a signal (6 = -112.6
p.p.m.) within the wide base of the strong FBAL signal. For true
quantification of FHPA, urine samples were also analysed at pH
2.5, which shifted the FHPA signal to -116.8 p.p.m.
The daily urinary excretion of FU and its catabolites was 56%
oftheinjected dose and -90% ofthe excretion occurredduring the
first 12 h (Table 3). Unmetabolized FU was almosttotally excreted
in the 0-12 h fractions. FBAL was by far the main metabolite as it
represented 84% ofthe excreted metabolites.FUH2 made up0.1%,
FUPA 3% and F- 13% of the excreted catabolites. Only small
amounts of FHPA and FAC were observed. FHPA represented
-0.1% and FAC 0.004% ofthe injected FU dose.
DISCUSSION
This study demonstrates for the first time that the last catabolite of
FU in IPRL and in rats is not FBAL. Metabolism progresses
furthergiving rise to FHPA and FAC.
In order to demonstrate the biotransformation of FU into FAC,
all the experiments were carried out with solutions ofFU prepared
immediately before use so as to avoid formation of degradation
products ofFU. Indeed, previous studies from our group (Lemaire
et al, 1992, 1994) indicated that the cardiotoxicity ofFU was due,
at least in the isolated perfused rabbit heart model, to degradation
compounds of this drug, namely fluoromalonic acid semi-alde-
hyde(FMASAld) andfluoroacetaldehyde(Facet). These are found
in commercial solutions and are formed over time in the basic
medium required to dissolve FU. FMASAId is chemically trans-
formed into Facet, which is extensively metabolized into FAC.
Thus, the solutions of FU injected in IPRL or in rats had to be
initially devoid ofthese two compounds.
Mukherjee and Heidelberger (1960) failed to demonstrate the
presence of FAC on paper chromatographic analysis of the urine
and tissues ofmice and ofcat urine afterinjection of6-['4C]FU. In
a study of the pharmacokinetics and tissue distribution of 3-
[3H]FBAL in rats, Zhang et al (1992), using high-performance
liquid chromatography (HPLC), only detected FBAL in urine and
detected mainly conjugates of FBAL with bile acids in the liver.
Using '9F-NMR, Hull et al (1988) detected FHPA in the urine of
patients treated with FU, although they referred to it as compound
U2and it was not identified. Two explanations could account for
these observations. The first is that only small amounts of FHPA
and FAC are formed. The second is that chromatographic determi-
nation of FAC involves complex and specific methodological
procedures (Ray et al, 1981; Okuno et al, 1982; Kramer, 1984;
Ozawa and Tsukioka, 1987; Burke et al, 1989; Mori et al, 1996).
The high water solubility and the high polarity of FAC make it
difficult to separate from water. Moreover, water often interferes
with the derivatization reaction (esterification) required to reduce
polarity and improve sensitivity for GC assay or to introduce a
chromophore for HPLC determination. The limits of FAC detec-
tion for currently available techniques are reported in Table 4. The
minimal amount of derivatized FAC that could be detected with
chromatographic techniques is much lower than the level of FAC
detectable with '9F-NMR. However, the minimal amount of FAC
required to carry out the entire process (extraction from aqueous
medium, derivatization and sometimes column chromatography
clean-up ofderivatized FAC) in accurate conditions is ofthe same
order ofmagnitude for '9F-NMR and chromatographic techniques
(except for the GC method of Ozawa and Tsukioka, 1987). The
relative lack of sensitivity of '9F-NMR is compensated by: (1) the
possibility of a direct analysis of the crude sample without any
extraction and/or derivatization procedures; and (2) the specific
detection offluorinated compounds avoiding the problem ofinter-
fering components often encountered in the detection oflow levels
ofFAC (Burke et al, 1989). To our knowledge, no assay ofFHPA
has been reported in literature.
FBAL and F were the main catabolites in the experiments with
FU (Table 2). We have no ready explanation for the significantly
higher amount ofF observed at the low dose ofFU. This observa-
tion is nevertheless supported by other experiments not reported
here in which commercial solutions of FU or pure FU adminis-
tered in combination with cisplatin were injected into IPRL at a
dose of 15 mg of FU kg-' body weight and led to similar data. It
has recently been shown that L-alanine-glyoxylate aminotrans-
ferase II (AlaAT-II; EC 2.1.6.44) catalysed the elimination of F
from FBAL (Porter et al, 1995). The literature on the inhibitory
effect of P-fluoro-a-amino acids on transaminase reactions
(Walsh, 1983) indicates that the Schiff's base intermediate formed
with the pyridoxal phosphate cofactor of these enzymes can
eliminate HF to form an enamine that deactivates the enzyme.
Moreover, a ,B-alanine transaminase has been isolated from
Streptomyces griseus and was found to be fully inhibited after
incubation with FBAL (Yonaha et al, 1985). It was therefore
possible to envisage that the large amounts ofFBAL formed in our
experiments with FU at 45 mg kg-'body weight could inactive the
defluorinating enzyme. However, Porter et al (1995) reported that
AlaAT-IIpurified from rat liver was not inactivated significantly
during 1h of FBAL dehalogenation. To explain our data, one
might therefore evoke that either the behaviour of the enzyme is
different for longer periods of time (3 h in our experiments) or
other(s) pyridoxal phosphate enzyme(s) is(are) involved in FBAL
defluorination, as already suggested (Spears et al, 1990; Porter et
al, 1995). Although we have no evidence ofan identical cell pene-
tration ofthe two FBAL enantiomers, the slightly lower amount of
F formed in the experiments with [RS]-FBAL relative to the
experiments with FU at 15 mg kg-' body weight (Table 2) is in
agreement with the report that [R]-FBAL was the preferred enan-
tiomer for the defluorinating activity in rat liver homogenates
(Porter et al, 1995).
The signal at -110.1 p.p.m. observed in all the FU 45mg kg-'
bodyweightexperimentsand in only one out ofthe five experiments
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at 15 mg of FU kg-' body weight, has not been identified. Its
chemical shift led us to propose that it corresponds to a compound
resulting from an interaction of FBAL involving its amino group
with a constituent of the perfusion medium that could have been
liberated by the liver. We have already detected this kind of
compound in plasma containing FBAL (Martino et al, 1987). The
higher level of FBAL could explain the higher level of this
compound in the experiments at45 mg ofFU kg-' body weight.
By analogy with the metabolism of P-alanine (Griffith, 1986),
we propose the following scheme for the metabolism of FBAL.
The enzymes of 1-alanine catabolism are probably also involved
in the catabolism ofFBAL. FMASAld and Facet were not detected
in our experiments as they are very reactive. The spontaneous
decarboxylation of malonic acid semi-aldehyde, the non-fluori-
nated analogue of FMASAld, is well documented (Pihl and
Fritzson, 1955). During the metabolization of fluorinated ethanes
into FAC in rats, intermediate Facet was also undetected in urine
and kidney extracts (Keller et al, 1996).
H2N-CH2-CHF-COOH IOHC-CHF-COOH) - (OHC-CH2F) -4 HOOC-CH2F
FBAL FMASAId Facet FAC
HOH2C-CHF-COOH
FHPA
The first step in f-alanine catabolism is a transamination reac-
tion to form malonic acid semi-aldehyde catalysed by hepatic
transaminases, namely 3-alanine-pyruvate aminotransferase (EC
2.6.1.18), f-alanine-oxoglutarate aminotransferase (EC 2.6.1.19)
and D-3-aminoisobutyrate-pyruvate aminotransferase (EC 2.6.1.40)
(Griffith, 1986; Tamaki et al, 1990). Even ifwe found no evidence
of this assertion in literature, the low levels of FHPA and FAC
obtained in our experiments are probably as a result of FBAL
being is a poor substrate for one or several enzymes of the cata-
bolic pathway of 3-alanine. Moreover, it has been reported that FU
is a competitive inhibitor of EC 2.6.1.19 and EC 2.6.1.40 with
respect to 3-alanine while FBAL inactivates EC 2.6.1.40 (Kaneko
et al, 1992). The larger amount of injected FU in IPRL experi-
ments at45 mg kg-' body weight could thus explain that there is no
relationship between the doses of injected FU and the amounts of
FHPA and FAC formed. The levels of FHPA and FAC obtained in
the experiments with FBAL were nearly half the amounts formed
in the experiments with FU at 15 mg kg-' body weight (Table 2).
This is probably due to the metabolization of the sole [R] enan-
tiomer, which is the enantiomer formed during the metabolization
ofFU (Gani et al, 1985).
FAC is a highly cardiotoxic and neurotoxic poison (Pattison and
Peters, 1966). FHPA does not generate cardiotoxic symptoms on
the isolated perfused rabbitheart model at a dose of0.09 gmol kg-'
body weight but is highly cardiotoxic on this model at a high dose
(14 ,umol kg-' body weight) (unpublished results). The levels of
FAC and FHPA found in perfusates of rat livers and in rat urine
were low. However, as the patients are normally treated for several
days (even weeks) with FU at the therapeutic dose of 15 mg kg-',
and as FAC is known to accumulate in the organism (Meldrum and
Bignell, 1957), a cumulative toxicity of FAC (and possibly also
FHPA) could explain cardio- and/or neurotoxic effects of FU in
patients. Moreover, it has been demonstrated that FBAL, the
precursor ofFHPA and FAC, accumulated in rats and was retained
up to 8 days in various tissues, mainly liver, heart and brain (Zhang
et al, 1992). FBAL may well be further metabolized in these
tissues over long periods of time. These observations could
account for the delayed onset of cardiotoxic or neurotoxic
symptoms with respect to the beginning of treatment in patients
receiving FU (Moore et al, 1990; Anand, 1994).
The results ofthe present study along with those oftwo previous
ones (Lemaire et al, 1992, 1994) show that the cardiotoxicity of
FU might have at least two origins. The first is the presence of
fluorinated impurities in commercial solutions ofFU derived from
the degradation of FU in the basic medium required for its solubi-
lization, which are metabolized into FHPA and FAC. The second is
the metabolism ofFU itselfinto these two cardiotoxic compounds.
We have demonstrated the presence ofFAC and FHPA in urine of
patients treated with FU (Lemaire et al, 1992, 1996). As FU
solutions are not pure, FAC and FHPA could arise from both the
metabolization of impurities and the metabolism of FU itself. We
have shown that a part ofFHPA came from FU metabolism but we
could not demonstrate it for FAC (Lemaire et al, 1996).
On the basis of our results, the cardiotoxicity (and possibly the
neurotoxicity) ofFU could be attenuated by: (1) using formulations
that are made up immediately before injection to avoid degradation
ofFU in solution (a lyophilisate form for example); and (2) the use
of an inhibitor of the catabolism of FU (e.g. ethynyluracil
(Baccanari et al, 1993) to prevent formation ofFBAL and its subse-
quent metabolization into the toxic FHPA and FAC.
ABBREVIATIONS
FU, 5-fluorouracil; FAC, fluoroacetate; 19F-NMR, fluorine-19
nuclear magnetic resonance; FHPA, a-fluoro-J-hydroxypropionic
acid; IPRL, isolated perfused rat liver; FBAL, ox-fluoro-p-alanine;
Cr(acac)3, chromium (III) acetylacetonate; FUOH, 5,6-dihydro-6-
hydroxy-5-fluorouracil; CFBAL, N-carboxy-a-fluoro-p-alanine;
6, chemical shift; FBAL [R]-gluc3, FBAL [S]-gluco, FBAL [R]-
gluca, FBAL [S]-gluca, adducts of a-fluoro-a-alanine with ,B-
glucose and a-glucose; FUPA, a-fluoro-p-ureidopropionic acid;
F-, fluoride ion; FUH2, 5,6-dihydro-5-fluorouracil; FMASAld,
fluoromalonic acid semi-aldehyde; Facet, fluoroacetaldehyde;
AlaAT-II, L-alanine-glyoxylate aminotransferase II
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